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OBJECTIVES: To examine the association between teriparatide adherence and
health care utilization and costs in “real world” U.S. hip fracture (HFx) patients.
METHODS: A large U.S. administrative claims database was used to identify pa-
tients aged 50 with an HFx between January 1, 2002-December 31, 2010 (first
observed HFx HFx index). All patients included had 6months of pre-HFx index
continuous enrollment (baseline) and no baseline teriparatide, cancer, or Paget’s
disease. Patients initiating teriparatide post-HFx index were followed from initia-
tion (exposed period) until censoring at switch to bisphosphonates, disenrollment,
36 months post-HFx index, cancer, or Paget’s disease. Adherence was measured as
the proportion of days covered (PDC) by teriparatide during the exposed period
(teriparatide PDC). Outcomes were repeated HFx and per-patient per-month (PPPM)
inpatient costs and number of inpatient admissions, outpatient costs, pharmacy
costs, and total costs. Multivariable Generalized Linear Models examined the asso-
ciation between teriparatide PDC (0.5 ‘low,’ 0.5-0.8 ‘medium,’ 0.8 ‘high’) and
the outcomes, adjusting for important patient characteristics. RESULTS: Study
included 824 patients; mean age 75 years, 90% female; 29% low PDC; 27% medium
PDC; 44% high PDC. In multivariable analyses, high adherence was significantly (all
P0.05) associated with increased PPPM pharmacy costs (low$621; medi-
um$1,093; high$1,572), but the lowest PPPM inpatient costs (low$963; me-
dium$960; high$629), number of inpatient admissions (incidence rate ratio vs.
high1.26 [low] and 1.28 [medium]), and outpatient costs (low$1087; medi-
um$1068; high$776). PPPM total costs differed significantly across the teripa-
ratide PDC groups (all P0.05) and were highest in the medium PDC group
(low$2599; medium$3163; high$2869). Too few repeated hip fractures
(low11; medium6; high2) occurred to complete multivariable analysis.
CONCLUSIONS:Among HFx patients newly-initiating teriparatide, significantly in-
creased pharmacy costs associated with greater teriparatide adherence were offset
by significantly lower inpatient admissions as well as inpatient and outpatient
costs.
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OBJECTIVES: Neuropathic pain (NeP) is a chronic condition endured by those who
have suffered damage to their somatosensory system. This damage can often re-
sult from various concomitant diseases. The condition can have a severe effect on
the level of quality of life (QoL). The purpose of this abstract is to investigate the
level of pain and impact on QoL of patients who suffer from NeP relative to recorded
pain levels. METHODS: Data were drawn from the 2012 Adelphi NeP Disease Spe-
cific Programme, a cross sectional survey involving 121 primary care physicians
and 292 specialists across France, Germany, Italy, Spain and UK. Physicians pro-
vided data on diagnosis and treatment patients, patients filled a self-completion
questionnaire which included the EQ-5D and Brief Pain Inventory questionnaires
(BPI; Interference measure). Patients were split into those who have peripheral
(N2033), central (N301) or both peripheral and central (P&C) condition(s)
(N165) and by categorising patients by peripheral conditions causing NeP.
RESULTS: A total of 3956 patients were included, of whom 2499 completed both
EQ5D and BPI. For patients suffering with, peripheral, central and P&C, BPI values
were 4.34, 4.70 and 4.77 respectively whereas EQ5D values were 0.591, 0.535 and
0.486 respectively. All differences between peripheral, central and P&C were sta-
tistically significant (P0.01). Average scores across the entire sample were EQ-5D
0.577, BPI 4.41. Certain conditions were associated with lower QoL and greater pain,
notably radiculopathy (N472, EQ-5D 0.553, BPI 4.66), fibromyalgia (N189, EQ-5D
0.514, BPI 5.06) and alcoholism (N84, EQ-5D 0.544, BPI 4.93) all p0.01 compared to
population means. CONCLUSIONS: These data show an inverse relationship be-
tween level of pain and the QoL experienced by patients using the EQ-5D and BPI.
This was particularly evident amongst patients with P&C and within NeP caused by
radiculopathy, fibromyalgia and alcoholism. Better pain control would therefore
lead to improvements in QoL.
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OBJECTIVES: The HS-FOCUS questionnaire was used to monitor patient reported
outcomes for mucopolysaccharidosis II (MPS II, Hunter Syndrome) patients. Pre-
liminary item analysis suggested that some of the items were redundant and/or
not informative. The objective of this study was to shorten HS-FOCUS without
compromising the psychometric properties of the original patient and parent ver-
sions while reducing the respondent’s burden. METHODS: Data collected in a ran-
domized trial were used. Final items were selected based on their content validity,
per clinicians’ input and by item performance as described below. Reliability, va-
lidity, and ability to detect change were assessed in the shortened version of the
HS-FOCUS. RESULTS: Forty-nine patients above 12 years old and 84 parents com-
pleted the HS-FOCUS. Items were removed owing to ambiguous wordings, floor
effects ( 60%), high inter-item correlations ( 0.90) and inadequate content or
clinical relevance. The Sleeping domain was removed from both the shortened
patient (32 items) and parent versions (35 items), which kept 5 functional domains.
The internal consistency and test-retest reliability were 0.70 for all domains ex-
cept the Breathing domain in patients. The test-retest reliability was assessed
using responses at Baseline and Week 18 and was 0.70 for all domains except the
Schooling/Work for parents’ version. Significant correlation (0.30) with similar
concepts of other instruments and the 6-Minute-Walk test demonstrated concur-
rent validity. Scores were significantly different in all domains among levels of
disability as measured by CHAQ disability score (CHAQ-DIS). Changes in domain
scores were responsive to changes in patients’ health status also measured by the
CHAQ-DIS. CONCLUSIONS: The shortened HS-FOCUS will reduce patient and par-
ent burden without compromising its measurement properties. The shortened
HS-FOCUS is a reliable and valid instrument for use in clinical trials or registries,
with increased ability to detect change compared to the original version.
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OBJECTIVES: ZQOL is the first and largest UK-wide cross-sectional study to explore
burden associated with HZ and PHN. Findings have previously highlighted that HZ
and PHN are painful conditions that significantly impact patients’ lives. However,
only limited real-world research exploring the presentation of HZ and PHN and the
patient-reported and economic impact of HZ and PHN has been conducted.
METHODS: The UK ZQOL study comprised 229 HZ and 152 PHN patients over the
age of 50. Patients completed validated patient-reported outcome measures and a
study-specific questionnaire exploring HZ and PHN presentation and patient-re-
ported impact. Recruiting doctors provided information regarding patients’ disease
presentation and medical resource use. RESULTS: Results indicate that HZ patients
experience a range of non-pain/non-rash symptoms prior to and following the
onset of the HZ rash, including sleep disturbance (50.2%), headaches (31.4%) and
nausea (27.9%), and that these persist in PHN patients. Both HZ and PHN patients
presented with pain, rash or numbness primarily on the torso (HZ-59%; PHN-66%)
or head/neck (HZ-30%; PHN-49%). 62.0% of HZ patients presented within a week of
experiencing pain where their shingles rash appeared. PHN patients experienced
pain for an average of 3.5 years; 25% experienced numbness. Doctors report pre-
scribing multiple medications for HZ (e.g. analgesics (71.2%) and antivirals (69.4%))
and PHN (e.g. antidepressants (59.2%) and level 1 analgesics (55.3%)). While fre-
quency of consultations, referrals or emergency care is low among HZ patients
(3.5%),PHN patients saw their doctor an average of 9.5 times; 14.5% received refer-
rals - contributing further to direct costs. Indirect costs for HZ and PHN manifest in
significant time lost from normal activities, including taking time off work (82.1%).
CONCLUSIONS: ZQOL study findings provide important ‘real-world’ information
regarding the presentation of HZ and PHN and highlight unmet needs that contrib-
ute to both patient-reported and economic burden in these populations.
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OBJECTIVES: To identify those symptoms and impacts with chronic low back pain
(cLBP) considered by patients to be the most bothersome for the purpose of iden-
tifying relevant concepts to assess in a new patient-reported outcome (PRO) mea-
sure for cLBP. METHODS: Adults (18-80 years) with clinical diagnosis of cLBP of
non-malignant origin present for at least 3 months and a current pain score 4 on
a 0-10 numerical rating scale (NRS) were recruited from 5 U.S. clinical sites and
Germany. Forty-three individual qualitative patient interviews were conducted
using a semi-structured interview guide designed to elicit relevant symptoms and
impacts. At the close of the qualitative interviews, patients rated their most both-
ersome symptoms and most difficult impacts using a 0-10 numerical rating scale
(NRS). Rating results (mean SD) were summarized for all symptoms and impacts
using descriptive statistics. RESULTS: Participant mean age was 48.613.0, major-
ity were female (53.5%) and 74.4% of participants described their racial/ethnic
group as White/Caucasian (Non-Hispanic). Mean pain intensity was 6.71.3. Pa-
tients rated most number of symptoms they had reported as being highly bother-
some on the NRS, with the highest ratings observed for - excruciating pain
(9.60.8); sharp pain (8.71.3); shooting pain (8.61.6); electric shocks/jolts
(8.02.0); spasms (7.72.7); cramping (7.52.4); burning pain (7.42.1); throbbing
pain (7.02.4); radiating pain (6.92.8); aching pain (6.92.5); and pins and needles
(6.71.6). The highest impact difficulty ratings included difficulty with: stairs
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